Do These 3 Healthcare Stocks Need a Checkup?
The pharmaceutical industry is highly competitive, and currently, the leading company in the sector is likely Eli Lilly (NYSE: LLY). That's driven by the fact that Eli Lilly makes the weight loss drugs Zepbound and Mounjaro, which together account for over 50% of the company's revenue. That's an interesting statistic because it highlights both the risk and opportunity that exists in the drug sector.
If you own or are considering buying pharma laggards (NYSE: PFE), Bristol Myers Squibb (NYSE: BMY), and (NYSE: MRK), here's a checkup on their businesses, and some reasons why you might want to buy them.
To get the bad news out of the way right up front, Pfizer, Bristol Myers Squibb, and Merck have all missed out on the early success of a new class of weight loss drugs known as GLP-1 drugs. Wall Street tends to favor innovators and first movers, so these three drug giants, despite long and successful histories, are deeply unloved right now.
Source Fool.com
Pfizer Inc. Aktie
Die Community neigt bei Pfizer Inc. zu Buy-Einschätzungen, mehr als zu Sell-Einschätzungen.
Das Kursziel von 27 € für Pfizer Inc. weist auf eine leichte Verbesserung gegenüber dem aktuellen Kurs von 23.59 € hin.
